Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update

Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the results from its annual meeting of shareholders held earlier today.

Results of Annual Meeting

Based on the proxies received and the vote conducted at the meeting, all tabled resolutions were approved by the shareholders of the Company, including the election of the following directors for the ensuing year: Don Cilla, Brian Bloom, Theresa Matkovits, Juergen Froehlich, Armand Balboni and Rochelle Stenzler.

Voting results for each director are summarized below:

Name of Nominee	Percentage of Votes For	Percentage of Votes Against
Don Cilla	15,441,269 (86.24%)	2,463,125 (13.76%)
Brian Bloom	15,444,109 (86.26%)	2,460,285 (13.74%)
Theresa Matkovits	17,601,894 (98.31%)	302,500 (1.69%)
Juergen Froehlich	17,602,394 (98.31%)	302,000 (1.69%)
Armand Balboni	15,431,769 (86.19%)	2,472,625 (13.81%)
Rochelle Stenzler	17,599,053 (98.29%)	305,340 (1.71%)

Shareholders also approved the re-appointment of PricewaterhouseCoopers, LLP, Chartered Accountants, as the independent auditor of the Company for the ensuing year and authorized the directors of the Company to fix their remuneration.

The Company has filed a report of the voting results on all resolutions voted on the Meeting on the Company’s SEDAR+ profile at www.sedarplus.ca.

Corporate Update

Since Appili’s last annual meeting, the Company has made significant progress. Most recently, the Company’s ATI-1501 program for the treatment of anaerobic bacterial infections, received U.S. Food and Drug Administration (“FDA”) approval on September 22, 2023. The approval of this product, with the brand name of LIKMEZ^TM, entitles Appili to receive royalties and milestone payments from its partner Saptalis Pharmaceuticals LLC.